Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(8.18%)
INR 136.85
(8.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.9 Billion INR | -44.14% |
| 2022 | 5.19 Billion INR | 4.24% |
| 2021 | 4.98 Billion INR | 13.19% |
| 2020 | 4.4 Billion INR | 17.0% |
| 2019 | 3.76 Billion INR | 9.34% |
| 2018 | 3.44 Billion INR | 15.39% |
| 2017 | 2.98 Billion INR | 10.8% |
| 2016 | 2.69 Billion INR | 12.17% |
| 2015 | 2.39 Billion INR | 33.95% |
| 2014 | 1.79 Billion INR | 18.63% |
| 2013 | 1.51 Billion INR | 11.8% |
| 2012 | 1.35 Billion INR | 36.77% |
| 2011 | 987.59 Million INR | -67.33% |
| 2010 | 3.02 Billion INR | 216.08% |
| 2009 | 956.4 Million INR | 12.43% |
| 2008 | 850.65 Million INR | 500.94% |
| 2007 | 141.55 Million INR | 384.76% |
| 2006 | 29.2 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 711.4 Million INR | 1.32% |
| 2023 FY | 2.9 Billion INR | -44.14% |
| 2023 Q1 | 1.58 Billion INR | 151.89% |
| 2023 Q2 | 1.53 Billion INR | -2.64% |
| 2023 Q3 | 1.41 Billion INR | -8.24% |
| 2023 Q4 | 702.13 Million INR | -50.3% |
| 2022 Q2 | 1.46 Billion INR | -3.63% |
| 2022 Q3 | 1.57 Billion INR | 7.14% |
| 2022 FY | 5.19 Billion INR | 4.24% |
| 2022 Q4 | 627.85 Million INR | -60.11% |
| 2022 Q1 | 1.52 Billion INR | 89.53% |
| 2021 Q4 | 804.2 Million INR | -36.75% |
| 2021 Q2 | 1.43 Billion INR | -2.03% |
| 2021 FY | 4.98 Billion INR | 13.19% |
| 2021 Q3 | 1.27 Billion INR | -11.5% |
| 2021 Q1 | 1.46 Billion INR | 97.12% |
| 2020 FY | 4.4 Billion INR | 17.0% |
| 2020 Q4 | 743.99 Million INR | -40.46% |
| 2020 Q3 | 1.24 Billion INR | -0.51% |
| 2020 Q2 | 1.25 Billion INR | 11.59% |
| 2020 Q1 | 1.12 Billion INR | 130.85% |
| 2019 Q3 | 1.17 Billion INR | 8.23% |
| 2019 Q2 | 1.08 Billion INR | 0.27% |
| 2019 Q1 | 1.08 Billion INR | 175.5% |
| 2019 Q4 | 487.53 Million INR | -58.59% |
| 2019 FY | 3.76 Billion INR | 9.34% |
| 2018 Q1 | 957.63 Million INR | 67.97% |
| 2018 Q4 | 393.73 Million INR | -62.41% |
| 2018 Q3 | 1.04 Billion INR | 1.57% |
| 2018 Q2 | 1.03 Billion INR | 7.69% |
| 2018 FY | 3.44 Billion INR | 15.39% |
| 2017 Q2 | 759.07 Million INR | -6.91% |
| 2017 FY | 2.98 Billion INR | 10.8% |
| 2017 Q1 | 815.43 Million INR | -34.54% |
| 2017 Q3 | 977.5 Million INR | 28.78% |
| 2017 Q4 | 570.12 Million INR | -41.68% |
| 2016 Q4 | 1.24 Billion INR | 28.92% |
| 2016 Q2 | 1.09 Billion INR | 26.52% |
| 2016 FY | 2.69 Billion INR | 12.17% |
| 2016 Q1 | 861.6 Million INR | 87.22% |
| 2016 Q3 | 966.24 Million INR | -11.36% |
| 2015 Q1 | 560.76 Million INR | 253.11% |
| 2015 FY | 2.39 Billion INR | 33.95% |
| 2015 Q4 | 460.21 Million INR | -38.15% |
| 2015 Q3 | 744.05 Million INR | 5.46% |
| 2015 Q2 | 705.5 Million INR | 25.81% |
| 2014 FY | 1.79 Billion INR | 18.63% |
| 2014 Q4 | 158.81 Million INR | -74.71% |
| 2014 Q3 | 627.93 Million INR | 7.92% |
| 2014 Q2 | 581.87 Million INR | 22.03% |
| 2014 Q1 | 476.82 Million INR | 2269.88% |
| 2013 Q3 | 518.13 Million INR | -11.79% |
| 2013 Q1 | 527.53 Million INR | 156.47% |
| 2013 Q4 | 20.12 Million INR | -96.12% |
| 2013 FY | 1.51 Billion INR | 11.8% |
| 2013 Q2 | 587.4 Million INR | 11.35% |
| 2012 Q2 | 294.12 Million INR | -29.38% |
| 2012 FY | 1.35 Billion INR | 36.77% |
| 2012 Q1 | 416.5 Million INR | 0.0% |
| 2012 Q3 | 434.43 Million INR | 47.71% |
| 2012 Q4 | 205.69 Million INR | -52.65% |
| 2011 FY | 987.59 Million INR | -67.33% |
| 2010 FY | 3.02 Billion INR | 216.08% |
| 2009 FY | 956.4 Million INR | 12.43% |
| 2008 FY | 850.65 Million INR | 500.94% |
| 2007 FY | 141.55 Million INR | 384.76% |
| 2006 FY | 29.2 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.715% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 92.604% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 75.072% |
| Granules India Limited | 7.18 Billion INR | 59.598% |
| Indoco Remedies Limited | 4.74 Billion INR | 38.893% |
| Achyut Healthcare Limited | 1.6 Million INR | -180248.664% |
| Ajanta Pharma Limited | 30.46 Billion INR | 90.474% |
| Alkem Laboratories Limited | 32.83 Billion INR | 91.162% |
| Alpa Laboratories Limited | 156.14 Million INR | -1758.383% |
| Brooks Laboratories Limited | 51.18 Million INR | -5569.812% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -11.591% |
| Bajaj HealthCare Limited | 985.34 Million INR | -194.497% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -104.465% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.973% |
| Eris Lifesciences Limited | 4.94 Billion INR | 41.294% |
| FDC Limited | 5.34 Billion INR | 45.746% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 95.705% |
| Gufic Biosciences Limited | 1.07 Billion INR | -169.257% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -36.608% |
| Ipca Laboratories Limited | 13.91 Billion INR | 79.146% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -275.197% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6186.962% |
| Lasa Supergenerics Limited | 291.17 Million INR | -896.59% |
| Laurus Labs Limited | 3.01 Billion INR | 3.62% |
| Lupin Limited | 95.67 Billion INR | 96.967% |
| Mankind Pharma Limited | 23.15 Billion INR | 87.467% |
| Medicamen Biotech Limited | 335.16 Million INR | -765.78% |
| Medico Remedies Limited | 161.84 Million INR | -1692.967% |
| Megasoft Limited | 49.52 Million INR | -5758.928% |
| NATCO Pharma Limited | 10.05 Billion INR | 71.149% |
| Piramal Pharma Limited | 19.91 Billion INR | 85.428% |
| RPG Life Sciences Limited | 1.63 Billion INR | -77.426% |
| Sigachi Industries Limited | 579.88 Million INR | -400.41% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.118% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -106.86% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -207.917% |
| Unichem Laboratories Limited | 6.72 Billion INR | 56.856% |
| Wanbury Limited | 1.16 Billion INR | -149.956% |
| Windlas Biotech Limited | 1 Billion INR | -188.304% |
| ZIM Laboratories Limited | 1.01 Billion INR | -186.441% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 93.279% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 5.687% |
| Divi's Laboratories Limited | 14.17 Billion INR | 79.521% |
| Hester Biosciences Limited | 908.84 Million INR | -219.287% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 3.124% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -164.044% |
| Bal Pharma Limited | 389.89 Million INR | -644.264% |
| Strides Pharma Science Limited | 9.16 Billion INR | 68.329% |
| Venus Remedies Limited | 1.91 Billion INR | -51.429% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 5.614% |
| Nectar Lifesciences Limited | 625.55 Million INR | -363.881% |
| Shilpa Medicare Limited | 2.18 Billion INR | -33.075% |
| Aarti Drugs Limited | 1.16 Billion INR | -148.554% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -164.089% |
| Suven Life Sciences Limited | 109.75 Million INR | -2544.018% |
| Ind-Swift Limited | 946.56 Million INR | -206.562% |
| Valiant Laboratories Limited | 36.28 Million INR | -7896.39% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 65.525% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 36.638% |
| Themis Medicare Limited | 782.85 Million INR | -270.67% |
| Hikal Limited | 2.48 Billion INR | -16.71% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 86.454% |
| Novartis India Limited | 470.1 Million INR | -517.275% |
| Wockhardt Limited | 6.4 Billion INR | 54.659% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.924% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -17801.69% |
| Neuland Laboratories Limited | 2.92 Billion INR | 0.954% |
| Morepen Laboratories Limited | 1.98 Billion INR | -46.007% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -603.594% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -329.169% |